Figure 7. In vivo effects of TRAIL treatment on TAM and tumor growth.

A-B. Anti-tumor effect of TRAIL treatment (0,01 g/kg) on primary tumor growth and spontaneous lung metastases (mean ±SE, 7 mice per group; representative experiment of two performed with similar results. C. Flow cytometry analysis of blood monocytes from TRAIL-treated or untreated mice; monocytes and in particular Ly6C^High expressing monocytes are significantly reduced after 48 hrs treatment. D. Flow cytometry analysis of TAM from TRAIL-treated or untreated mice; TAM and in particular the Ly6C^Inter subset are significantly reduced after treatment; in both C and D results are shown as % of positive cells relative to total CD45⁺ cells (mean ±SE, 7 mice per group) E. Immunohistochemistry of tumor sections from TRAIL-treated and untreated mice stained for F4/80, CD31 and CD206. The immunoreactive area for macrophages (F4/80, CD206) and number of vessels (CD31) are shown on the right panels. Results are calculated as mean from five microscope fields for each sample, 7 mice per group. Images were analyzed using Image-Pro Analyzer software. Original magnification 20X. Statistical analysis: *P < 0.05, ** P < 0.01, *** P < 0.001 (Student's t test).